-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Pfizer and BioNTech jointly announced that the new crown vaccine BNT162b2 jointly developed by the two parties has shown 100% efficacy and a strong antibody immune response in a phase 3 clinical trial conducted in adolescents aged 12-15.
BNT162b2 is a new coronavirus vaccine based on mRNA technology.
In this phase 3 clinical trial involving 2260 adolescents aged 12-15 years, 18 COVID-19 patients with symptoms were found in the placebo group (n=1129), but none in the vaccine group (n=1131) Symptoms of COVID-19 patients.
At the same time, BNT162b2 is well tolerated in this adolescent population, and the side effects are comparable to those previously observed in 16-25 year olds.
The two companies also announced that the Phase 1/2/3 seamless clinical study in children from 6 months to 11 years of age had been launched last week.
Note: The original text has been deleted
Reference materials:
[1] PFIZER-BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS OF PIVOTAL COVID-19 VACCINE STUDY IN ADOLESCENTS.